TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8915274

Group type: EXPERIMENTAL
Intervention: Fast ingestion group with 20 mg of oral metoclopramide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard ingestion group without additional drugs
Number of subjects: 64
Study: 1667048

Group type: EXPERIMENTAL
Intervention: Fragmin (KABI) 300 anti‐Xa U/kg/24h subcutaneously for 6‐10 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fragmin (KABI) 240‐360 anti‐Xa U/kg/24h subcutaneously for 6‐10 days
Number of subjects: 72
Study: 6416593

Group type: EXPERIMENTAL
Intervention: Advice plus booklet plus the offer of nicotine gum
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Advice plus booklet
Number of subjects: 1938

Group type: COMPARATOR
Intervention: Non‐intervention controls
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Nicotine gum (self-selected subgroup using more than one box of 105 pieces)
Number of subjects: 1938
Study: 30744092

Group type: EXPERIMENTAL
Intervention: Olive leaf extract (OLE) supplementation (100 mg oleuropein equivalent to 20 g of olive leaf) for nine weeks.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo supplementation for nine weeks.
Number of subjects: 32
Study: 28654312

Group type: EXPERIMENTAL
Intervention: T'ai chi combined with health education twice weekly for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 43
Study: 26239288

Group type: EXPERIMENTAL
Intervention: DAS-steered treat-to-target (T2T) strategy
Number of subjects: 0
Study: 25816655

Group type: EXPERIMENTAL
Intervention: Three-port laparoscopic cholecystectomy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy (control group)
Number of subjects: 118
Study: 22932146

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 86
Study: 19887279

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg after obtaining 2 responses, 4 mg/kg with post‐tetanic count between 1 and 3 responses, 12 to 16 mg/kg for rescue reversal)
Number of subjects: 0
Study: 17383057

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit vaccine (Sub/MF59)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Conventional subunit vaccine (Subunit)
Number of subjects: 238
Study: 12708121

Group type: EXPERIMENTAL
Intervention: Pranayam training (nadishuddhi, mukh-bhastrika, pranav and savitri pranayams) for 20 minutes daily for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no pranayam training)
Number of subjects: 24
Study: 9892329

Group type: EXPERIMENTAL
Intervention: 5 mg warfarin
Number of subjects: 53

Group type: COMPARATOR
Intervention: 10 mg warfarin
Number of subjects: 53
Study: 8904935

Group type: EXPERIMENTAL
Intervention: Moderately brief advice from general practitioners
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Minimal advice from doctors
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: More involved intervention from doctors
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Reinforcement contact following a 2-hour training workshop
Number of subjects: 4500
Study: 2052629

Group type: EXPERIMENTAL
Intervention: Eccentric contractions with maximal effort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concentric contractions with maximal effort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eccentric contractions at equal power levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentric contractions at equal power levels
Number of subjects: 0
Study: 7058424

Group type: EXPERIMENTAL
Intervention: Accurette endometrial sampler
Number of subjects: 42
Study: 31636242

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pyridostigmine-glycopyrrolate
Number of subjects: 102
Study: 30946887

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Laser treatment (control)
Number of subjects: 466
Study: 28029326

Group type: EXPERIMENTAL
Intervention: O-DHAP (Ofatumumab 1,000 mg)
Number of subjects: 447

Group type: COMPARATOR
Intervention: R-DHAP (Rituximab 375 mg/m2)
Number of subjects: 447
Study: 26392096

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (25 Gy in five daily fractions over 1 week)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Commonly used radiotherapy (40 Gy in 15 daily fractions over 3 weeks)
Number of subjects: 98
Study: 23816898

Group type: EXPERIMENTAL
Intervention: Moving with device (MD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Moving without device (MND)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non‐moving (NM)
Number of subjects: 22
Study: 21765361

Group type: EXPERIMENTAL
Intervention: Standard amino acid intake (1.5 g · kg(‐1) · day(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High amino acid intake (3.0 g · kg(‐1) · day(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 9
Study: 19357135

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day low molecular weight heparin (LMWH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 150
Study: 16967770

Group type: EXPERIMENTAL
Intervention: Leg extension exercise at 30%, 60%, and 90% of 1-RM
Number of subjects: 20
Study: 16268981

Group type: EXPERIMENTAL
Intervention: Warm water immersion (33-34 degrees C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Land conditions
Number of subjects: 12
Study: 10322586

Group type: EXPERIMENTAL
Intervention: Concentric isokinetic knee strength and power assessment using Cybex 6000 System
Number of subjects: 96
Study: 8565163

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected (AC) 99mTc-sestamibi SPECT
Number of subjects: 119

Group type: COMPARATOR
Intervention: Uncorrected (NC) 99mTc-sestamibi SPECT
Number of subjects: 119
Study: 1928019

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT) among severe users
Number of subjects: 42

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT) among severe users
Number of subjects: 42
Study: 7095565

Group type: EXPERIMENTAL
Intervention: Aspirin (two tablets four times a day for 24 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bufferin (two tablets four times a day for 24 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Paracetamol (two tablets four times a day for 24 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (two tablets four times a day for 24 hours)
Number of subjects: 10
Study: 31655876

Group type: EXPERIMENTAL
Intervention: QuikClot Radial hemostatic pad (QC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard mechanical compression (SC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: QuikClot Radial hemostatic pad (QC) in TRA subgroup
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard mechanical compression (SC) in TRA subgroup
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: QuikClot Radial hemostatic pad (QC) in TUA subgroup
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard mechanical compression (SC) in TUA subgroup
Number of subjects: 200
Study: 30458677

Group type: EXPERIMENTAL
Intervention: Self‐concept threat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Own‐reputation threat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 29794581

Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement (TDR)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both TDR and nonoperative treatment
Number of subjects: 126
Study: 27078151

Group type: EXPERIMENTAL
Intervention: CHO+PROT (0.8 g carbohydrate + 0.4 g protein·kg(‐1)·h(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO (1.2 g carbohydrate·kg(‐1)·h(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLA (placebo without energy)
Number of subjects: 8
Study: 24684807

Group type: EXPERIMENTAL
Intervention: Intravascular microdialysis catheter
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Triple-lumen central venous catheter with integrated microdialysis function
Number of subjects: 80
Study: 22445212

Group type: EXPERIMENTAL
Intervention: Medication (fluoxetine or venlafaxine)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 20073385

Group type: EXPERIMENTAL
Intervention: Worksite wellness program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 17494789

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 31

Group type: COMPARATOR
Intervention: APAP
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both CPAP and APAP
Number of subjects: 31
Study: 15638752

Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics in infant formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotic- and prebiotic-containing infant formulas
Number of subjects: 0
Study: 12145773

Group type: EXPERIMENTAL
Intervention: Diet + exercise group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diet group
Number of subjects: 29
Study: 10409957

Group type: EXPERIMENTAL
Intervention: Rosidal K short-stretch compression bandage
Number of subjects: 52

Group type: COMPARATOR
Intervention: SurePress long-stretch compression bandage
Number of subjects: 52
Study: 7717556

Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope
Number of subjects: 35

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 35

Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 35
Study: 1828415

Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice daily (n = 112)
Number of subjects: 220

Group type: COMPARATOR
Intervention: 20 mg piroxicam once daily (n = 108)
Number of subjects: 220
Study: 31601842

Group type: EXPERIMENTAL
Intervention: 1000 mg of pomegranate extract (PomX)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 8 oz of pomegranate juice (PomJ)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: PomX and PomJ
Number of subjects: 74
Study: 28765288

Group type: EXPERIMENTAL
Intervention: Follow-up noncontrast computed tomography ischemic lesion volume (ILV) in brain areas of high mRS relevance
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Total ischemic lesion volume (ILV)
Number of subjects: 254
Study: 26059264

Group type: EXPERIMENTAL
Intervention: Guideline-concordant prescribing of ACE-inhibitors/statins in early clinics
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Guideline-concordant prescribing of statins in early clinics
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Control group (late clinics)
Number of subjects: 6500
Study: 23348685

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 25% corn dried distillers grains (DDG)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 25% DDG with corn starch (DDG+S)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Corn grain-based basal diet (CON)
Number of subjects: 21
Study: 21605389

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention based on Clinical Practice Guideline recommendations over a six-month period.
Number of subjects: 2937

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 2937
Study: 19139736

Group type: EXPERIMENTAL
Intervention: Intra-BM injection (IBMI) of one UCB unit
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous (i.v.) injection of one UCB unit
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 10
Study: 17720409

Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 70
Study: 15060361

Group type: EXPERIMENTAL
Intervention: Internal/transnasal perforating lateral osteotomy (2‐mm straight chisel)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: External/percutaneous perforating lateral osteotomy (2‐mm straight chisel)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Internal transnasal perforating lateral osteotomy (2‐mm straight chisel)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Continuous osteotomy (4‐mm curved, guarded osteotome)
Number of subjects: 75
Study: 11509937

Group type: EXPERIMENTAL
Intervention: 100 mg/kg intravenous immunoglobulin
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 250 mg/kg intravenous immunoglobulin
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 500 mg/kg intravenous immunoglobulin
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: All doses of intravenous immunoglobulin
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 250 mg/kg and 500 mg/kg intravenous immunoglobulin
Number of subjects: 618
Study: 9604558

Group type: EXPERIMENTAL
Intervention: 20% CO2-enriched air (unconditioned stimulus)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 13% CO2-enriched air (unconditioned stimulus)
Number of subjects: 96
Study: 7804585

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study: 3243930

Group type: EXPERIMENTAL
Intervention: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 80 mg/dL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermally administered scopolamine (TTS-scopolamine) with acute alcohol intake (BAC 130 mg/dL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermally administered scopolamine (TTS-scopolamine)
Number of subjects: 12
Study: 31172325

Group type: EXPERIMENTAL
Intervention: Immersive VR
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional VR
Number of subjects: 31
Study: 29661991

Group type: EXPERIMENTAL
Intervention: Information on FDA roles in regulating tobacco
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Information about the scientific basis of regulations
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Information on FDA's commitment to protecting the public
Number of subjects: 1766

Group type: COMPARATOR
Intervention: No information on FDA roles in regulating tobacco
Number of subjects: 1766

Group type: COMPARATOR
Intervention: No information about the scientific basis of regulations
Number of subjects: 1766

Group type: COMPARATOR
Intervention: No information on FDA's commitment to protecting the public
Number of subjects: 1766
Study: 28466494

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried cortical bone allograft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Deproteinized cancellous bovine bone xenograft
Number of subjects: 20
Study: 25107900

Group type: EXPERIMENTAL
Intervention: 0.5 mg IVT-AFL every 4 weeks (0.5q4)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2 mg IVT-AFL every 4 weeks (2q4)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2 mg IVT-AFL every 8 weeks (2q8)
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab every 4 weeks (Rq4)
Number of subjects: 94
Study: 24005242

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Number of subjects: 316

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 316
Study: 21439275

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B administration for 3 months in nondiabetic group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B administration for 3 months in diabetic group
Number of subjects: 61
Study: 18513835

Group type: EXPERIMENTAL
Intervention: Oral bolus (OB) feeding
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasogastric tube bolus (TB) feeding
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasogastric tube drip (TD) feeding
Number of subjects: 12
Study: 17186725

Group type: EXPERIMENTAL
Intervention: Cooling-blood and detoxicating combined with clearing-heat and resolving dampness (PA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Strengthening-Pi and warming-yang (PB)
Number of subjects: 43
Study: 14662587

Group type: EXPERIMENTAL
Intervention: High-risk prethreshold ROP eyes (risk, 0.15-1.0)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Low-risk prethreshold ROP eyes (risk, <0.15)
Number of subjects: 613
Study: 10735611

Group type: EXPERIMENTAL
Intervention: Terlipressin (2mg/iv injection)
Number of subjects: 20
Study: 8866072

Group type: EXPERIMENTAL
Intervention: WTL + Prompt (leaflet provided and prompted to read)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: WTL only (leaflet provided but not prompted)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control 1 (dental health education leaflet with no prompting)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control 2 (no additional written material, verbal information provided)
Number of subjects: 66
Study: 1477649

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF administered subcutaneously (s.c.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (5.5 and 11 micrograms/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (5.5 + 11 micrograms/kg)
Number of subjects: 24
Study: 6367451

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition counseling based on a fat-modified eating pattern
Number of subjects: 0
Study: 30686751

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 UI once per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uremic serum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25(OH)D3 and 1,25(OH)2D3 incubation
Number of subjects: 0
Study: 29465250

Group type: EXPERIMENTAL
Intervention: Esomeprazole intravenous bolus every 12 hours for 72 hours with second look endoscopy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Continuous high dose esomeprazole infusion for 72 hours
Number of subjects: 127
Study: 27974612

Group type: EXPERIMENTAL
Intervention: Active HD-tDCS on left DLPFC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Active HD-tDCS on right DLPFC
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active HD-tDCS on left M1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active HD-tDCS on right M1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham HD-tDCS on left DLPFC
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham HD-tDCS on right DLPFC
Number of subjects: 120
Study: 25085607

Group type: EXPERIMENTAL
Intervention: High-level endurance training combined with cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-level exercise combined with cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study: 21997554

Group type: EXPERIMENTAL
Intervention: High resolution manometry (HRM) Clouse plots
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional line tracings
Number of subjects: 36
Study: 20417038

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Passive relaxation control condition
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) and Progressive Muscle Relaxation (PMR)
Number of subjects: 39
Study: 17345071

Group type: EXPERIMENTAL
Intervention: Levodopa 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg (1 x 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg (3 x 100 mg over 3 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14699490

Group type: EXPERIMENTAL
Intervention: Adefovir 10 mg daily + Lamivudine
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Adefovir + Lamivudine (group B)
Number of subjects: 135
Study: 11693277

Group type: EXPERIMENTAL
Intervention: ACS Multilink Duet stent
Number of subjects: 240
Study: 9822086

Group type: EXPERIMENTAL
Intervention: Stenting in vessels >=3 mm (Group I)
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Stenting in vessels <3 mm (Group II)
Number of subjects: 1298
Study: 7853449

Group type: EXPERIMENTAL
Intervention: Ball-bouncing (diverted attention)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calm seated (focused attention)
Number of subjects: 38
Study: 2570233

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 105
Study: 72290

Group type: EXPERIMENTAL
Intervention: 40 mg oxprenolol
Number of subjects: 24
Study: 30714980

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) plus traditional dysphagia training (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Traditional dysphagia training alone (n = 16)
Number of subjects: 33
Study: 28878437

Group type: EXPERIMENTAL
Intervention: Intensive health guidance using IoT devices (measuring daily activity, body weight, and blood pressure)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional medical guidance (non-IoT control group with measurement devices without feedback)
Number of subjects: 101
Study: 26836126

Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate (CS) and deproteinized bovine bone (group CB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Biphasic CS and alloplast (group CA)
Number of subjects: 16
Study: 24655119

Group type: EXPERIMENTAL
Intervention: IV alcohol infusion to attain and clamp the breath alcohol concentration (BrAC) at 50 mg%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22153056

Group type: EXPERIMENTAL
Intervention: Tobacco control course
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 546